Juva Life Announces Flōs, New Branded Cannabis Flower Product Line
New Branded Cannabis Product Line Diversifies Company Product Offerings; Compliments Pharmaceutical Research
VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the launch of the Company’s new product line, Flōs, a branded line of flower and pre-rolled cannabis products.
“Our Flōs line provides consumers with high-quality cannabis products without paying top shelf prices, and further expands our product category to capitalize on the massive market growth within California,” said Doug Chloupek, CEO and Founder of Juva. “We’re thrilled that the completion of our Stockton cultivation facility construction has doubled our output capacity, creating space for us to offer new consumer packaged goods that our customers are requesting.”
Flōs is Latin for blossom, or flower, and the unique beauty of the cannabis flower is on full display with Juva’s new product line. Featuring eighth ounce quantities, pre-rolls in one gram quantity, and half ounces of flower products, these meticulously-selected cultivars are budget-friendly without sacrificing quality.
The Flōs flower line is available for distribution throughout the entire state of California, and is also available through Juva Delivery, which is a division of vertically integrated Juva Life, Inc. Juva Delivery also offers contactless pre-payment options through Paytender, a secure, fee-free online payment service. The Flōs flower line will also be featured in the future at the Company’s upcoming retail store, which has been approved for licensing by the City of Redwood City, and is currently under construction.
Each Flōs product begins with the highest quality cannabis cultivars grown at the Company’s 30,000-square-foot Stockton, California, cannabis cultivation facility. Once harvested and cured, the material is then moved to Juva’s distribution division for final processing and statewide distribution. To find available products locally in the San Francisco Peninsula area, visit here.
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
